Shanghai Shyndec subsidiary acquires lactulose oral solution rights

Shanghai Shyndec Pharmaceutical announced that its controlled subsidiary, Sinopharm Zhijun (Pingshan) Pharmaceutical Co., Ltd. (Sinopharm Zhijun Pingshan), has signed a "Drug Marketing Authorization Transfer Agreement" with Anhui Meilai Pharmaceutical Co., Ltd. Under this agreement, Anhui Meilai will transfer the marketing authorization for its Lactulose Oral Solution (15ml:10g) to Sinopharm Zhijun Pingshan for a total transfer fee of 5.86 million yuan.

This acquisition is aligned with Shanghai Shyndec's long-term development strategy to enrich its product pipeline, particularly in the chronic disease treatment area, and is expected to enhance Sinopharm Zhijun Pingshan's market competitiveness. The Lactulose Oral Solution (15ml:10g) received its drug registration certificate on January 8, 2025. According to the announcement, the transaction will not have a significant impact on the company's current operating performance.

The agreement covers all rights and interests of the product globally, including marketing authorization, full-chain operation, and intellectual property rights, without any third-party restrictions. The transfer fee of 5.86 million yuan (including tax) will be paid in installments based on the progress of the contract. The company cautions that the transfer of marketing authorization and changes in production sites involve a lengthy process with inherent uncertainties.